Modulation of cardiac remodeling by adenosine:: In vitro and in vivo effects

被引:31
作者
Villarreal, F
Zimmermann, S
Makhsudova, L
Montag, AC
Erion, MD
Bullough, DA
Ito, BR
机构
[1] Univ Calif San Diego, Med Ctr, Dept Med, San Diego, CA 92103 USA
[2] Metabasis Therapeut Inc, Dept Pharmacol, La Jolla, CA USA
[3] Metabasis Therapeut Inc, Dept Med Chem, La Jolla, CA USA
关键词
adenosine; myocardial infarction; cardiac remodeling;
D O I
10.1023/A:1025401026441
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The increasing incidence of congestive heart failure has stimulated efforts to develop pharmacologic strategies to prevent or reverse the associated process of adverse cardiac remodeling. The possibility of utilizing endogenously generated factors that are capable of inhibiting this process is beginning to be explored. Adenosine, has been described as a retaliatory autacoid with homeostatic activities in the regulation of myocardial blood flow, catecholamine release, and reduction of injury resulting from periods of ischemia. Adenosine exerts a variety of actions that are consistent with the concept that it can reduce or inhibit the process of cardiac remodeling. In this manuscript, the basics of adenosine metabolism, its cell surface receptors and beneficial actions on the cardiovascular system are reviewed. In addition new, in vitro and in vivo data will be presented supporting the concept that adenosine exerts actions that may ameliorate adverse cardiac remodeling.
引用
收藏
页码:17 / 26
页数:10
相关论文
共 66 条
[1]  
ABDELFATTAH AS, 1994, J THORAC CARDIOV SUR, V108, P269
[2]  
Alhaddad IA, 2000, CAN J CARDIOL, V16, P463
[3]   Nucleoside transport inhibition by draflazine in unstable coronary disease [J].
Andersen, K ;
Dellborg, M ;
Swedberg, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) :7-13
[4]   SERUM TUMOR-NECROSIS-FACTOR LEVELS IN ACUTE MYOCARDIAL-INFARCTION AND UNSTABLE ANGINA-PECTORIS [J].
BASARAN, Y ;
BASARAN, MM ;
BABACAN, KF ;
ENER, B ;
OKAY, T ;
GOK, H ;
OZDEMIR, M .
ANGIOLOGY, 1993, 44 (04) :332-337
[5]  
BAUER BM, 1997, AM J PHYSIOL, V273, pG1297
[6]   Adenosine A1 agonist at reperfusion trial (AART):: Results of a three-center, blinded, randomized, controlled experimental infarct study [J].
Baxter, GF ;
Hale, SL ;
Miki, T ;
Kloner, RA ;
Cohen, MV ;
Downey, JM ;
Yellon, DM .
CARDIOVASCULAR DRUGS AND THERAPY, 2000, 14 (06) :607-614
[7]   REGULATION OF COLLAGEN PRODUCTION BY THE BETA-ADRENERGIC SYSTEM [J].
BERG, RA ;
MOSS, J ;
BAUM, BJ ;
CRYSTAL, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (05) :1457-1462
[8]   Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation [J].
Boyle, DL ;
Sajjadi, FG ;
Firestein, GS .
ARTHRITIS AND RHEUMATISM, 1996, 39 (06) :923-930
[9]   LIMITATION OF INFARCT EXPANSION AND VENTRICULAR REMODELING BY LATE REPERFUSION - STUDY OF TIME-COURSE AND MECHANISM IN A RAT MODEL [J].
BOYLE, MP ;
WEISMAN, HF .
CIRCULATION, 1993, 88 (06) :2872-2883
[10]  
BRACKETT LE, 1994, BIOCHEM PHARMACOL, V47, P801